Key points are not available for this paper at this time.
The identification of oncogenic mutations in diffuse large B-cell lymphoma (DLBCL) has led to the development of drugs that target essential survival pathways, but whether targeting multiple survival pathways may be curative in DLBCL is unknown.
Building similarity graph...
Analyzing shared references across papers
Loading...
Christopher Melani
National Institutes of Health
Rahul Lakhotia
National Cancer Institute
Stefania Pittaluga
University of Maryland, Baltimore
New England Journal of Medicine
National Institutes of Health
National Cancer Institute
University of Maryland, Baltimore
Building similarity graph...
Analyzing shared references across papers
Loading...
Melani et al. (Wed,) studied this question.
synapsesocial.com/papers/68e6405ab6db6435875d292d — DOI: https://doi.org/10.1056/nejmoa2401532